Zhou, Kexun <br/><br/>
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  10 2019 
 - 98-101 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2019.08.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Biomarkers, Tumor<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cost-Benefit Analysis<br/>Female<br/>Health Care Costs<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Markov Chains<br/>Molecular Targeted Therapy<br/>Prognosis<br/>Propensity Score<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Treatment Outcome